T-cell adoptive immunotherapy using tumorinfiltrating T cells and genetically engineered TCR-T cells

International Immunology

Volumn 28, Issue 7, 2016, Pages 349-353

  Ikeda, Hiroaki ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Adoptive T cell therapy; Gene engineering; Neoantigen; T cell receptor; Tumor infiltrating lymphocytes

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ARTICLE; GENETIC ENGINEERING; HUMAN; PRIORITY JOURNAL; T CELL ADOPTIVE IMMUNOTHERAPY; T LYMPHOCYTE; TUMOR INFILTRATING T CELL; ADVERSE DRUG REACTION; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; NEOPLASM; PROCEDURES; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE;

CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84977110495     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxw022     Document Type: Article

References (30)

1. Dunn, G. P., Bruce, A. T., Ikeda, H. et al. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991.
2. Sharma, P. and Allison, J. P. 2015. The future of immune checkpoint therapy. Science 348:56.
3. Maus, M. V., Grupp, S. A., Porter, D. L. et al. 2014. Antibodymodified T cells: CARs take the front seat for hematologic malignancies. Blood 23:2625.
4. Rosenberg, S. A. and Restifo, N. P. 2015. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62.
5. Gattinoni, L., Powell, D. J., Jr, Rosenberg, S. A. et al. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6:383.
6. Noonan, K. A., Huff, C. A., Davis, J. et al. 2015. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci. Transl. Med. 7:288ra78.
7. Restifo, N. P., Dudley, M. E. and Rosenberg, S. A. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12:269.
8. Tran, E., Turcotte, S., Gros, A. et al. 2014. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641.
9. Chapuis, A. G., Ragnarsson, G. B., Nguyen, H. N. et al. 2013. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci. Transl. Med. 5:174ra27.
10. Butler, M. O., Friedlander, P., Milstein, M. I. et al. 2011. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci. Transl. Med. 3:80ra34.
11. Morgan, R. A., Dudley, M. E., Wunderlich, J. R. et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126.
12. Johnson, L. A., Morgan, R. A., Dudley, M. E. et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535.
13. Robbins, P. F., Morgan, R. A., Feldman, S. A. et al. 2011. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29:917.
14. Robbins, P. F., Kassim, S. H., Tran, T. L. et al. 2015. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1- reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21:1019.
15. Bendle, G. M., Linnemann, C., Hooijkaas, A. I. et al. 2010. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 6:565.
16. Cohen, C. J., Li, Y. F., El-Gamil, M., Robbins, P. F., Rosenberg, S. A. and Morgan, R. A. 2007. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67:3898.
17. Cohen, C. J., Zhao, Y., Zheng, Z. et al. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66:8878.
18. Okamoto, S., Mineno, J., Ikeda, H. et al. 2009. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 69:9003.
19. Provasi, E., Genovese, P., Lombardo, A. et al. 2012. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18:807.
20. Parkhurst, M. R., Yang, J. C., Langan, R. C. et al. 2011. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19:620.
21. Morgan, R. A., Chinnasamy, N., Abate-Daga, D. et al. 2013. Cancer regression and neurological toxicity following anti-MAGEA3 TCR gene therapy. J. Immunother. 36:133.
22. Cameron, B. J., Gerry, A. B., Dukes, J. et al. 2013. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5:197ra103.
23. Linette, G. P., Stadtmauer, E. A., Maus, M. V. et al. 2013. Cardiovascular toxicity and titin cross-reactivity of affinityenhanced T cells in myeloma and melanoma. Blood 122:863.
24. Di Stasi, A., Tey, S. K., Dotti, G. et al. 2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365:1673.
25. Gros, A., Parkhurst, M. R., Tran, E. et al. 2016. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22:433.
26. Themeli, M., Kloss, C. C., Ciriello, G. et al. 2013. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31:928.
27. Davis, J. L., Theoret, M. R., Zheng, Z. et al. 2010. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 16:5852.
28. Chodon, T., Comin-Anduix, B., Chmielowski, B. et al. 2014.Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin. Cancer Res. 20:2457.
29. Kageyama, S., Ikeda, H., Miyahara, Y. et al. 2015. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin. Cancer Res. 21:2268.
30. Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K. et al. 2015. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21:914